Who Owns TCRX?

TScan Therapeutics, Inc. — Institutional Ownership & 13F Holdings

$1.31

+0.04 (+3.17%)

Market Cap

$73.1M

Shares Outstanding

55,824,722

Institutional Holders

92

Total Inst. Value

$54.1M

% of Float Held

85.0%

QoQ Holder Change

+36

Institutional data as of Q1 2025

New Positions

19

Closed Positions

17

Increased

33

Decreased

18

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1Lynx1 Capital Management LP$7.4M5,357,347
2BVF INC/IL$6.7M4,889,474
3BlackRock, Inc.$6.7M4,878,833
4ADAGE CAPITAL PARTNERS GP, L.L.C.$4.8M3,500,000
5BAKER BROS. ADVISORS LP$3.8M2,784,792
6VANGUARD GROUP INC$3.3M2,356,746
7Propel Bio Management, LLC$2.9M2,087,139
8Checkpoint Capital L.P.$2.8M2,017,650
9Deer Management Co. LLC$1.7M1,245,504
10Alphabet Inc.$1.5M1,077,080

Biggest Buyers & Sellers This Quarter

Top Buyers

Famous Fund Managers

Related Stocks

Frequently Asked Questions

How many institutional investors hold TCRX?

As of Q1 2025, 92 institutional investors report holding TCRX (TScan Therapeutics, Inc.) in their 13F filings.

What percentage of TScan Therapeutics, Inc. is owned by institutions?

Institutional investors hold approximately 85.0% of TScan Therapeutics, Inc.'s float as reported in SEC 13F filings.

Which hedge fund owns the most TCRX?

The largest institutional holder of TCRX is Lynx1 Capital Management LP with $7.4M in shares.

Are institutions buying or selling TCRX?

This quarter, 19 institutions opened new positions in TCRX and 17 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.